Multiple sclerosis trial on pre-medication for infusions
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests a different pre-medication for people with multiple sclerosis who get infusions of ocrelizumab, ublituximab, or rituximab. The goal is to see if it reduces reactions to the infusion.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You read and speak English or Spanish.
- You are able to give permission to join the study.
- You have a diagnosis of multiple sclerosis.
- You are starting or currently getting ocrelizumab, ublituximab, or rituximab infusions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares rituximab and ocrelizumab in people with relapsing-remitting multiple sclerosis (MS) to see which medicine better controls MS activity. It may help reduce future relapses and new MRI lesions.
This trial tests a new way of taking Ocrelizumab as a shot under the skin, for people with MS who are already on a similar treatment and want to switch. The goal is to see if switching is safe and works well.
This trial tests an experimental drug called AZD0120 in adults with multiple sclerosis. It is designed for people with relapsing or progressive forms of MS who have not responded well to other treatments or have active disease.
This trial tests a new way to give the drug ublituximab (an injection under the skin) to people with relapsing multiple sclerosis. It compares different injection sites and a special auto-injector device to see how the body absorbs the drug and if it's safe.
This trial tests an experimental oral drug called VT7208 in both healthy volunteers and people with multiple sclerosis (MS). The goal is to see if it is safe and how the body processes it, which could lead to a new treatment option for MS.
This study looks at giving ocrelizumab treatments at home instead of in a clinic for people with MS. It’s meant to see if this approach is practical and acceptable while you keep receiving a medicine your MS doctor thinks you should continue.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.